Chronic Lymphocytic Leukemia | Specialty

The OncLive Chronic Lymphocytic Leukemia condition center page is a comprehensive resource for clinical news and expert insights on treatment advances and ongoing research in chronic lymphocytic leukemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs and updates with chronic lymphocytic leukemia therapy.

Zanubrutinib Provides ORR, PFS Benefits Over Ibrutinib in Relapsed/Refractory CLL/SLL

October 4th 2022

Zanubrutinib elicited significantly higher response rates and survival benefits compared with ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma .

Duvelisib Loses Support for CLL/SLL Indication Following ODAC Meeting

September 23rd 2022

In an 8 to 4 vote, the FDA’s Oncologic Drugs Advisory Committee voted that the final overall survival data submitted did not demonstrate a strong enough benefit-risk ratio for duvelisib for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after at least 2 prior therapies.

NVG-111 Generates Early Efficacy With Manageable Safety in Relapsed/Refractory CLL, MCL

September 14th 2022

The ROR1-targeting bispecific T-cell engager NVG-111 elicited promising responses with a manageable safety profile in patients with relapsed/refractory chronic lymphocytic leukemia or mantle cell lymphoma.

Obinutuzumab/Acalabrutinib/Venetoclax Triplet Misses the Mark in Relapsed/Refractory CLL

September 13th 2022

Obinutuzumab, acalabrutinib, and venetoclax following optimal debulking with bendamustine failed to meet the prespecified rate of undetectable minimal residual disease in the peripheral blood at the end of induction treatment in patients with relapsed/refractory chronic lymphocytic leukemia.

Dr. Al-Sawaf on the Benefit of Fixed-Duration Obinutuzumab/Venetoclax in CLL

August 29th 2022

Othman Al-Sawaf, MD, discusses the benefit of fixed-duration treatment with obinutuzumab plus venetoclax in chronic lymphocytic leukemia.

Fixed-Duration Ibrutinib Plus Venetoclax Wins EU Approval in Previously Untreated CLL

August 25th 2022

The European Commission has approved the fixed-duration, all-oral combination of ibrutinib and venetoclax for the frontline treatment of adult patients with chronic lymphocytic leukemia.

Dr. Lunning on the Evolution of BTK Inhibitors in CLL

August 24th 2022

Matthew A. Lunning, DO, FACP, discusses the evolution of BTK inhibitors in chronic lymphocytic leukemia.

Acalabrutinib With or Without Obinutuzumab Maintains Long-Term Survival Benefit in Untreated CLL

August 24th 2022

Jeff P. Sharman, MD, discusses the meaning of the long-term follow-up data from ELEVATE-TN, the efficacy of acalabrutinib regimens in patients with treatment-naïve chronic lymphocytic leukemia with deletion 17p or TP53 mutations, and factors to consider when adding obinutuzumab to acalabrutinib.

Dr. Mato on Factors for Choosing BTK Inhibitors or Venetoclax in CLL

August 22nd 2022

Anthony Mato, MD, MSCE, discusses the factors used to make treatment decisions between BTK inhibitors and venetoclax in chronic lymphocytic leukemia.

Dr. Ahn on Choosing Between Treatment Options in CLL

August 16th 2022

Inhye Ahn, MD, physician, discusses choosing between treatment options in chronic lymphocytic leukemia.

Dr. Ryan on Objectives for Investigating Ibrutinib Plus Obinutuzumab in R/R CLL

August 16th 2022

Christine Ryan, MD, discusses the objectives for investigating different sequencing options for ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Dr. Shadman on the Exploration of the CAR T-Cell Therapy MB-106 in NHL/CLL

August 8th 2022

Mazyar Shadman, MD, MPH, discusses the exploration of MB-106, a third-generation CD20-targeted autologous CAR T-cell therapy, in relapsed/refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia.

New Acalabrutinib Tablet Formulation Approved for Current Indications, Including CLL, SLL, and MCL

August 5th 2022

The FDA has approved a new tablet formulation of acalabrutinib for all current indications, including adult patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and for those with relapsed or refractory mantle cell lymphoma.

Dr. Lunning on Trials Evaluating BTK Inhibitors in CLL

August 3rd 2022

Matthew A. Lunning, DO, FACP, discusses trials evaluating BTK inhibitors in chronic lymphocytic leukemia.

Fixed-Duration Venetoclax/Obinutuzumab Provides Robust PFS Benefit in Untreated CLL

July 29th 2022

Othman Al-Sawaf, MD, discusses the 5-year follow-up data of the phase 3 CLL14 trial and emphasized the importance of fixed-duration treatments in high-risk patients with chronic lymphocytic leukemia.

Ibrutinib Plus Obinutuzumab Elicits Intriguing Survival Benefits in Relapsed/Refractory CLL

July 27th 2022

Christine Ryan, MD, discussed the evaluation of safety and efficacy of ibrutinib plus obinutuzumab in patients with relapsed/refractory CLL in the trial and how the results could result in another treatment option for patients with relapsed/refractory CLL.

Dr. Ryan on the Investigation of Ibrutinib Plus Obinutuzumab in Relapsed/Refractory CLL

July 26th 2022

Christine Ryan, MD, discusses the investigation of ibrutinib plus obinutuzumab in relapsed/refractory chronic lymphocytic leukemia.

Zanubrutinib Displays Improved Efficacy Vs Orelabrutinib in Relapsed/Refractory CLL/SLL and MCL

July 22nd 2022

Zanubrutinib demonstrated a significant improvement in progression-free survival compared with orelabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma or mantle cell lymphoma.

Zanubrutinib Showcases Superior PFS Benefit Over BR in Treatment-Naïve CLL/SLL, Including High-Risk Subsets

July 20th 2022

Zanubrutinib was found to significantly improve progression-free survival over a doublet comprised of bendamustine plus rituximab in patients with treatment-naïve chronic lymphocytic leukemia and small lymphocytic lymphoma, according to data from cohort 1 of the phase 3 SEQUOIA trial.

Pirtobrutinib Demonstrates Encouraging Efficacy, Favorable Safety in Previously Treated CLL/SLL

July 14th 2022

Pirtobrutinib continued to produce promising responses in heavily pretreated patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, irrespective of BTK C481 mutation status, reason for prior BTK inhibitor discontinuation, or other classes of previous therapy received.